Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. functions as a global biopharmaceutical enterprise, concentrating its efforts on the research, creation, advancement, production, and global commercialization of medicinal treatments for a diverse array of human diseases. The company's robust catalog of approved therapies includes: EYLEA injection, indicated for various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema that develops after retinal vein occlusion (both central and branch types). Dupixent injection, prescribed for managing atopic dermatitis and asthma in both adults and children. Libtayo injection, targeting metastatic or locally advanced cutaneous squamous cell carcinoma. Praluent injection, an adult treatment for heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease. REGEN-COV, developed to address COVID-19. Kevzara solution, utilized in adults for treating rheumatoid arthritis. Inmazeb injection, an intervention for infections caused by the Zaire ebolavirus. ARCALYST injection, for cryopyrin-associated periodic syndromes, encompassing familial cold auto-inflammatory syndrome and Muckle-Wells syndrome. ZALTRAP injection for intravenous infusion, used in the management of metastatic colorectal cancer. Beyond its marketed products, Regeneron also maintains an active development pipeline, with investigational therapies aimed at conditions affecting the eyes, allergic and inflammatory responses, cardiovascular and metabolic systems, infectious diseases, rare genetic disorders, oncology, pain management, and hematologic ailments. The company actively engages in strategic collaborations and licensing partnerships with a range of entities, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. Additionally, it holds agreements with the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority (BARDA), and AstraZeneca PLC. Established in 1988, Regeneron Pharmaceuticals, Inc. maintains its corporate headquarters in Tarrytown, New York.